Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms

Comparisons between everolimus and sunitinib regarding their efficacy and safety in neuroendocrine neoplasms (NENs) are scarce. We retrospectively analysed the clinicopathological characteristics and outcomes in 92 patients with well-differentiated (WD) NEN of different origin (57 pancreatic NENs (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Daskalakis, Kosmas, Tsoli, Marina, Angelousi, Anna, Kassi, Evanthia, Alexandraki, Krystallenia I, Kolomodi, Denise, Kaltsas, Gregory, Koumarianou, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528409/
https://www.ncbi.nlm.nih.gov/pubmed/31026812
http://dx.doi.org/10.1530/EC-19-0134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528409/
https://www.ncbi.nlm.nih.gov/pubmed/31026812
http://dx.doi.org/10.1530/EC-19-0134

Ejemplares similares